* NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

Technology Appraisal [Committee B] meeting minutes

**Minutes:** Confirmed

**Date and time:** Tuesday 19 February 2019, from 10am to 1pm

**Location:** 10 Spring Gardens London SW1A 2BU

# Committee members present

1. Professor Amanda Adler [Chair] Present for all items
2. Dr Carlo Berti Present for all items
3. Professor John Cairns Present for all items
4. Mr Mark Chapman Present for all items
5. Ms Susan Faulds Present for all items
6. Dr Mark Glover Present for all items
7. Mr Gareth Hooper Present for all items
8. Dr Megan John Present for all items
9. Dr Sanjay Kinra Present for all items
10. Dr Nicholas Latimer Present for all items
11. Mr Christopher O’Regan Present for all items 1 to 3
12. Professor Nicky Welton Present for all items
13. Mr Nigel Westwood Present for all items
14. Mr Tony Wootton Present for all items
15. Committee member Present for all items
16. Committee member Present for all items
17. Committee member Present for all items
18. Committee member Present for all items
19. Committee member Present for all items
20. Committee member Present for all items

# NICE staff present:

Helen Knight, Programme Present for all items

director

Nicole Elliott, Associate Present for all items

director

Jeremy Powell, Project Present for all items

manager

Adam Brooke, Technical Present for all items

analyst

Ahmed Elsada, Technical Present for all items

adviser

Professor Peter Clark, Chair Present for all items

Of NHS England Chemotherapy   
Clinical Reference Group and

National Clinical Lead for CDF

Helen Barnett, Medical editor Present for all items

Edgar Masanga, Business Present for all items

analyst

1. Introduction to the meeting
   1. The chair welcomed members of the committee and other attendees present to the meeting.
2. News and announcements
   1. None.
3. Appraisal of enzalutamide for treating non-metastatic hormone-relapsed prostate cancer [ID1359]
   1. Part 1 – Open session
      1. The Chair welcomed the invited expert, Professor Peter Clark, to the meeting and he introduced himself to the committee
      2. The chair welcomed the invited company representatives from Astellas
      3. The chair asked all committee members, clinical and patient experts, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.

* Dr Amanda Adler, Dr Carlo Berti, Professor John Cairns, Mr Mark Chapman, Ms Susan Faulds, Dr Mark Glover, Mr Gareth Hooper, Dr Megan John, Dr Sanjay Kinra, Dr Nicholas Latimer, Mr Christopher O'Regan, Professor Nicky Welton, Mr Nigel Westwood and Mr Tony Wootton all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of enzalutamide for treating non-metastatic hormone-relapsed prostate cancer [ID1359].
  + 1. The Chair/Vice Chair introduced the key themes arising from the consultation responses to the Appraisal Consultation Document [ACD] received from consultees, commentators and through the NICE website.
    2. discussed confidential information submitted for this item.
  1. Part 2 – Closed session [company representatives, clinical and patient experts, external group representatives and members of the public were asked to leave the meeting]
     1. The committee then agreed on the content of the Final Appraisal Determination [FAD]. The committee decision was reached choose option.
     2. The committee asked the NICE technical team to prepare the Final Appraisal Determination [FAD] in line with their decisions.

1. Appraisal of nivolumab with ipilumumab for untreated metastatic renal cell carconima [ID1182]
   1. The chair explained that this appraisal was being discussed in a closed session because the discussions followed directly from the closed session conclusions reached by the Committee at the 22 January meeting
   2. The Chair welcomed the invited expert Professor Peter Clark to the meeting and he introduced himself to the Committee
   3. The Chair welcomed company representatives from Bristol-Myers Squibb to the meeting
      1. The chair asked all committee members, clinical and patient experts, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
      2. Dr Amanda Adler, Dr Carlo Berti, Professor John Cairns, Mr Mark Chapman, Ms Susan Faulds, Dr Mark Glover, Mr Gareth Hooper, Dr Megan John, Dr Sanjay Kinra, Dr Nicholas Latimer, Professor Nicky Welton, Mr Nigel Westwood and Mr Tony Wootton all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of nivolumab with ipilimumab for untreated metastatic renal cell carcinoma [ID1182].
   4. Mr Diar Fattah declared a personal non-specific financial interest as he has received consultancy fees from Novartis in another disease area.
      1. It was agreed that Mr Fattah could participate in the appraisal
   5. Professor Peter Clark declared that he knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of nivolumab with ipilimumab for untreated metastatic renal cell carcinoma [ID1182].
   6. The Chair introduced the key issues arising from the Cancer Drugs Fund proposal submitted by the company.
   7. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
   8. The Chair then thanked the company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.
2. The committee asked the NICE technical team to prepare the Final Appraisal Determination [FAD] in line with their decisions.
3. Date of the next meeting

The next meeting of the Technology Appraisal (Committee B) will be held on Tuesday 26 March 2019 and will start promptly at 10am.